Munich Leukemia Laboratory MLL offers integrated findings for myelodysplastic syndromes

After the successful introduction of Integrated Findings for acute myeloid leukemia (AML) at the end of 2017, Münchner Leukämielabor GmbH (MLL) now also offers a version for myelodysplastic syndromes (MDS). The goal here is also to provide both a clear summary and detailed interpretation of the often complex constellation of individual cytomorphological, flow cytometry, and in particular cytogenetic and molecular genetic findings. Accordingly, the Integrated Findings for MDS provide the exact diagnosis according to the latest WHO classification and the categorization according to major prognostic scoring systems (IPSS, IPSS-R), as well as explanations of other relevant aspects by default This aims to assist with determining individual, patient-specific therapy concepts.
"The Integrated Findings for AML has invariably received positive feedback from clinics and practices who have requested test results. This has encouraged us to further refine our tool for the interpretation of MDS illnesses, which are often highly complex genetically", explains Professor Torsten Haferlach, Managing Director at MLL.

As before, the report is compiled by the experienced hematologists at MLL. The minimum requirements for this are information on the differential blood count during the submission of the sample, as well as the conducting of cytomorphological and cytogenetic MDS diagnostics at MLL. For AML, molecular genetics and ideally immunophenotyping are also necessary. For other entities such as multiple myeloma and CLL, the Integrated Findings are currently in the works.

The author

»Do you have questions regarding this article or do you need further information? Please send me an e-mail.«

Dr. med. Christian Pohlkamp

Internist, Hematologist and Oncologist
Head of Cytomorphology
Head of Customer Care

T: +49 89 99017-150